Terminated PHASE2 INTERVENTIONAL 3-arm NCT01726465

Methylprednisolone N Acetylcysteine in Hepatic Resections (MENHIR)

Phase II Randomized Double Blind Trial of Methylprednisolone and N-acetylcysteine in Hepatic Resections.

Sponsor: Istituto Clinico Humanitas

Conditions Insufficiency; Hepatic, Postoperative Ischemic Reperfusion Injury Liver Tumour

Interventions Methylprednisolone N-acetylcysteine

Updated 5 times since 2017 Last updated: Nov 9, 2013 Started: Nov 30, 2012 Primary completion: Oct 31, 2013 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The first phase was completed

Other terminated trials from Istituto Clinico Humanitas

See all terminations from Istituto Clinico Humanitas

A PHASE2 clinical study on Insufficiency; Hepatic, Postoperative and Ischemic Reperfusion Injury, this trial is terminated or withdrawn. The trial is conducted by Istituto Clinico Humanitas and has accumulated 5 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Istituto Clinico Humanitas

Data source: Istituto Clinico Humanitas

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rozzano, Italy